Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neuroone Medical Technologies (NMTC) Long-Term Deferred Tax (2021 - 2025)

Neuroone Medical Technologies' Long-Term Deferred Tax history spans 5 years, with the latest figure at $20.6 million for Q3 2025.

  • For Q3 2025, Long-Term Deferred Tax rose 7.32% year-over-year to $20.6 million; the TTM value through Sep 2025 reached $20.6 million, up 7.32%, while the annual FY2025 figure was $20.6 million, 7.32% up from the prior year.
  • Long-Term Deferred Tax reached $20.6 million in Q3 2025 per NMTC's latest filing, up from $19.2 million in the prior quarter.
  • In the past five years, Long-Term Deferred Tax ranged from a high of $20.6 million in Q3 2025 to a low of $8.9 million in Q3 2021.
  • Average Long-Term Deferred Tax over 5 years is $15.3 million, with a median of $15.6 million recorded in 2023.
  • Peak YoY movement for Long-Term Deferred Tax: soared 35.9% in 2022, then rose 7.32% in 2025.
  • A 5-year view of Long-Term Deferred Tax shows it stood at $8.9 million in 2021, then skyrocketed by 35.9% to $12.1 million in 2022, then increased by 29.65% to $15.6 million in 2023, then grew by 22.59% to $19.2 million in 2024, then rose by 7.32% to $20.6 million in 2025.
  • Per Business Quant, the three most recent readings for NMTC's Long-Term Deferred Tax are $20.6 million (Q3 2025), $19.2 million (Q3 2024), and $15.6 million (Q3 2023).